| Project/Area Number |
10670522
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
TANAKA Masatoshi Kurume University, School of Medicine, Lecturer, 医学部, 講師 (60179786)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YUTANI Shigeru Kurume University, School of Medicine, Assistant, 医学部, 助手 (20279160)
SHICHIJO Shigeki Kurume University, School of Medicine, Assistant professor, 医学部, 助教授 (30080592)
|
|---|
| Project Period (FY) |
1998 – 1999
|
| Project Status |
Completed (Fiscal Year 1999)
|
| Budget Amount *help |
¥3,100,000 (Direct Cost: ¥3,100,000)
Fiscal Year 1999: ¥1,500,000 (Direct Cost: ¥1,500,000)
Fiscal Year 1998: ¥1,600,000 (Direct Cost: ¥1,600,000)
|
|---|
| Keywords | Tumor rejection antigen / MAGE-4 / Hepatocellular carcinoma / Liver cirrhosis / Prediction of Cancer / 肝細胞癌 |
|---|
| Research Abstract |
The majority of hepatocellular carcinomas (HCC) in Japan are caused from liver cirrhosis (LC) patients who have long suffered with hepatitis virus infection. Development of a useful serum marker for prediction of HCC is needed for better treatment and care of these patients. We previously reported that the MAGE-4 protein in sera of both HCC and LC patients were significantly higher than those of the control.
This study has addressed whether level of MAGE-4 protein is useful for prediction of HCC by measurement of the serum MAGE-4 protein in LC (n=61) patients as a control at least 3 different times within 8 years. HCC was observed in 28 (46%) of these LC patients during this period, respectively. MAGE-4 protein was positive (>1.15 ng/ml) in 14 of 28 HCC patients (50%) before the diagnosis of LICC. And MAGE-4 protein was positive in only 3 of 33 LC patients (9%) who were not diagnosed as HCC. Levels of MAGE-4 protein in 7 or 5 patients were positive one or two year before the time of diagnosis of HCC, respectively. MAGE-4 protein decreased after the treatment of HCC in all the 6 patients tested, and became negative in 4 patients.
We then performed the uni-valiated analysis of the predicting risk factors of HCC : gender, age, scrum AST, AFP value and MAGE-4 in 28 patients diagnosed as HCC. AFP level (over 20 ng/ml) (p=0.02) and MAGE-4 protein level (p=0.01) were significant as a factor for prediction of HCC.
The multi-variated analysis was also performed. The MAGE-4 protein level in sera was the most significant risk factor for the prediction (p = 0.002).
Thus, level of serum MAGE-4 was better that the any other serum markers tested for prediction of HCC in LC patients.
Measurement of serum MAGE-4 could be a novel tool for prediction of HCC in LC patients.
|
